Export

Daclatasvir + sofosbuvir
Essential medicine status
General description

INN
Daclatasvir + sofosbuvir
Medicine type
Chemical agent
EML status history
First added in 2021 for Chronic hepatitis C
Changed in 2021 for Chronic hepatitis C
Changed in 2021 for Chronic hepatitis C
Changed in 2021 for Chronic hepatitis C
Changed in 2021 for Chronic hepatitis C
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
  • Oral > Solid: 60 mg + 400 mg